sec filing
AL
NASDAQ · ALPX
Alopexx, Inc.
Healthcare · Biotechnology
$9.95
Up+$0.01 (+0.10%)
Updated Sep 18, 2026, 12:27 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 79
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 48.96K
- Avg. volume
- 0
Price performance
ALPX price history
1M range · 16 trading sessions · Daily adjusted prices
ALPX closed at $9.95 after 16 trading sessions, up 0.30% for the selected period.
- Last close
- $9.95
- Period change
- +0.30%
- Period low
- $9.92
- Period high
- $9.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $9.95 | $9.95 | $9.94 | $9.95 | 48.96K |
| Sep 15, 2026 | $9.95 | $9.95 | $9.95 | $9.95 | 355.95K |
| Sep 14, 2026 | $9.96 | $9.96 | $9.95 | $9.95 | 201.53K |
| Sep 9, 2026 | $9.95 | $9.95 | $9.95 | $9.95 | 2.6K |
| Sep 8, 2026 | $9.95 | $9.95 | $9.94 | $9.94 | 3.29K |
| Sep 4, 2026 | $9.945 | $9.945 | $9.945 | $9.945 | 5.25K |
| Sep 3, 2026 | $9.94 | $9.9401 | $9.94 | $9.9401 | 431 |
| Sep 2, 2026 | $9.94 | $9.95 | $9.94 | $9.95 | 714 |
| Sep 1, 2026 | $9.94 | $9.94 | $9.94 | $9.94 | 734 |
| Aug 31, 2026 | $9.94 | $9.94 | $9.94 | $9.94 | 250.04K |
| Aug 27, 2026 | $9.95 | $9.95 | $9.92 | $9.92 | 3.09K |
| Aug 26, 2026 | $9.96 | $9.97 | $9.95 | $9.95 | 776 |
| Aug 25, 2026 | $9.93 | $9.95 | $9.93 | $9.95 | 248 |
| Aug 24, 2026 | $9.94 | $9.95 | $9.94 | $9.95 | 44.77K |
| Aug 21, 2026 | $9.93 | $9.93 | $9.9225 | $9.93 | 2.65K |
| Aug 20, 2026 | $9.91 | $9.92 | $9.91 | $9.92 | 446.28K |
Latest ALPX news
The latest Smart Investors Daily articles mentioning ALPX.
Stock researchCompany · Overview
ALPX research
Overview
Company profile and research snapshot.
Company profile
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabetes mellitus; and F598, a monoclonal antibody that has completed Phase I and pilot Phase II trials for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units. The company is headquartered in Cambridge, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.